Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Lilla Bűdi, Dániel Hammer, Rita Varga et al. · 2025 · Pathology and Oncology Research
ObjectivesSpingosine-1-phosphate (S1P) and ceramides are bioactive sphingolipids that influence cancer cell fate. Anti-ceramide antibodies might inhibit the effects of ceramide. The aim of this study was to assess the potential role of circulating S1P and anti-ceramide antibody as biomarkers in non-small cell lung cancer (NSCLC).MethodsWe recruited 66 subjects (34 controls and 32 patients with NSCLC). Patient history and clinical variables were taken from all participants. Venous blood samples were collected to evaluate plasma biomarkers. If bronchoscopy was performed, bronchial washing fluid
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Rui ZHENG, Xiaosong QIN, Wenjie LI et al. · 2011 · Chinese Journal of Lung Cancer
Background and objective It has been proven that Src played pivotal roles in carcinogenesis, cancer progression and metastasis. The aim of this study is to explore the roles of Src phosphorylation on lung cancer cells. Methods Western blot and immunoprecipitation was used to detect the expression and phosphorylation of Src in lung cancer cells. MTT and Boyden chamber assay was used to examine the effects of inhibition of Src phosphorylation on proliferation and invasion of lung cancer cells in vitro, respectively. Results pp60src was expressed in all lung cancer cell lines in this study. All 5
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
ZHU Yaling, YI Fengtao, DING Mengnan et al. · 2020 · Zhongliu Fangzhi Yanjiu
Objective To explore the effect of Kupffer cells (KCs) secretion on HCC cells after cryoablation and its mechanism. Methods Sixteen groups were divided:37℃ control group, three hypothermia groups(0℃, 5℃, 10℃), freeze-thaw necrotic substances group, three combined stimulation group and 8 parallel groups for each group. In the 8 parallel groups, pyrrolidine dithiocarbamate(PDTC) was added, and the final concentration was 100 μmol/ml. The concentration of TNF-α, IL-1β and INF-γ in 16 groups of KCs supernatant were determined by Elisa method. The expression of NF-κB protein in each group was detec
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Nieves Martínez-Lago, Ana Fernández-Montes, Marta Covela et al. · 2021 · BMC Cancer
Abstract Background Outcomes are poorer in metastatic colorectal cancer (mCRC) patients with BRAF V600E mutations than those without it, but the effect of these mutations on treatment response is unclear. This real-world study assessed the effects of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF V600-mutated mCRC. Methods This real-world, multicenter, retrospective, observational study included patients with BRAF V600-mutated mCRC treated in eight hospitals in Spain. The primary endpoints were overall survival (OS) and progression-free survi
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Jiawei Chen, Hongsheng Deng, Jiaxi He et al. · 2022 · Frontiers in Oncology
IntroductionThe interval between neoadjuvant immunochemotherapy and surgery in patients with non-small cell lung cancer (NSCLC) has not been well characterized. This study investigated the association between the time-to-surgery (TTS) interval and surgical–pathological outcomes.MethodClinical data of patients who received neoadjuvant immun-ochemotherapy followed by surgery for NSCLC between January 2019 and September 2021 were collected. The patients were divided into three groups based on TTS interval: the early-surgery group (ESG), the standard-surgery group (SSG), and the delayed-surgery gr
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Ruixue Yang, Xuejiao Zeng, Xierenguli Alimu et al. · 2025 · Cancer Immunology, Immunotherapy
Abstract Objective This study investigated the impact of innate lymphoid cell type 2 (ILC2s) on the function of regulatory T cells (Treg) and CD8+ T cells in chronic lymphocytic leukemia (CLL) through IL-9. Methods Peripheral blood samples were collected from CLL patients (n = 52) and healthy controls (n = 30). ILC2 proportions and IL-9 levels were assessed using flow cytometry and ELISA. Immunofluorescence staining was performed to stain GATA3, CRTH2, and IL-9 in cervical lymph nodes from CLL patients (n = 10) and control subjects with reactive lymphadenitis (n = 10). Correlation analysis bet
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Yong Li, Yong Li, Junlan Wu et al. · 2022 · Frontiers in Oncology
ObjectiveBrain metastasis from colorectal cancer (CRC) is rare. Although stereotactic radiotherapy (SRT) and stereotactic radiosurgery (SRS) are effective treatments for brain metastasis, reports on brain metastasis of CRC are limited. This study compared the efficacy of SRT and SRS for the treatment of brain metastases from CRC and analysed the related factors to reveal the specificity CRC-derived brain metastasis.MethodsA retrospective analysis of 116 patients with brain metastases from colorectal cancer was performed and included 56 patients in the SRT group and 60 patients in the SRS group
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Kai Zhou, Anqiang Wang, Jingtao Wei et al. · 2022 · Frontiers in Oncology
BackgroundHepatoid adenocarcinoma of the stomach (HAS) is a rare type of gastric cancer, but the role of perioperative chemotherapy is still poorly understood. The aim of this retrospective study was to investigate the associations between perioperative chemotherapy and prognosis of HAS.MethodWe retrospectively analyzed patients with locally advanced HAS who received radical surgery in Peking University Cancer Hospital between November 2009 and October 2020. Patients were divided into neoadjuvant chemotherapy-first (NAC-first) group and surgery-first group. The relationships between perioperat
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Guofeng Pan, Guofeng Pan, Guofeng Pan et al. · 2025 · Frontiers in Oncology
ObjectiveRadical gastrectomy for gastric cancer involves the en-bloc resection of the primary tumor and complete excision of the mesogastrium. However, the surgical boundaries and techniques for removing lymph nodes above the pylorus during gastric cancer surgery remain unclear. We aimed to investigate a novel, standardized approach for excising the right mesogastrium in gastric cancer patients undergoing suprapyloric lymphadenectomy, focusing on surgical techniques and outcomes.MethodsOur surgical technique includes identifying three key elements of the mesogastrium: the encircling portion, t
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
FU Hua, ZHOU Guochao, CAI Rongmin, SONG Xin, YANG Dinghua · 2025 · Zhongguo aizheng zazhi
Background and purpose: The resistance of pancreatic cancer to albumin-bound paclitaxel affects the therapeutic effect and prognosis. Signal transducer and activator of transcription 3 (STAT3) is one of the important molecules regulating the chemotherapy sensitivity of cancer cells. The liposome BP1003 targeting the antisense oligonucleotide of STAT3 mRNA can inhibit the expression of STAT3 and increase the chemotherapy sensitivity. However, the effect of BP1003 on the sensitivity of pancreatic cancer cells to albumin-bound paclitaxel remains unclear. The purpose of this study was to investiga
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Diego Raimondo, Antonio Raffone, Antonio Raffone et al. · 2022 · Frontiers in Oncology
Data about the oncological outcomes in women with borderline ovarian tumor (BOT) undergoing uterine-sparing surgery without ovarian preservation are poor. We aimed to assess the oncological outcomes in women with BOT undergoing uterine-sparing surgery without ovarian preservation. A multi-center observational retrospective cohort study was performed including all consecutive postmenopausal patients who underwent surgical treatment for BOT at three tertiary level referral centers for gynecologic oncology from January 2005 to December 2016. Patients were divided into two groups for comparisons:
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Lina Jans, Jan Brynhildsen, Joar Hofgaard et al. · 2025 · Infectious Agents and Cancer
Abstract Background Users of intrauterine devices (IUDs) have been found to have a lower incidence of cervical cancer in meta-analyses, but these studies have not been able to examine the influence of IUD type. The aim of this study is to investigate the incidence of de novo high-risk human papillomavirus (HPV) infections in relation to the reported use of contraceptive methods, with special regard to different types of IUDs. Methods A sample of participants in the national screening program for cervical cancer (n = 11,702) with a negative HPV test in 2017–2018 were included. Their subsequent
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Said Abu Alkhair Mohamed, Ihab Shafek Atta, Brian G. Rowan et al. · 2014 · Journal of the Egyptian National Cancer Institute
Our previous published data detected higher expression of total and active mitogen activated protein kinase (MAPK) in the epithelial vs. stromal cells of the endometrium. In the present work we compared the expression of ERK1/2 MAPK and estrogen receptor α (ERα) in epithelial versus stromal cells in benign human endometrial tissues. Laser capture microdissection was used to separate glandular epithelium and stromal cells from six frozen, proliferative phase endometrial specimens. Total and phosphorylated levels for ERK1/2 and ERα were measured by quantitation of signals from Western blots usin
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Jianfeng Li, Hongjie Zhu, Nanzhi Luo et al. · 2024 · Discover Oncology
Abstract The optimal surgical approach for elderly patients with early-stage non-small cell lung cancer (NSCLC) remains a topic of debate. A retrospective analysis was conducted on patients who underwent pulmonary resection for early-stage NSCLC at our single institution between January 2018 and December 2022. Propensity score matching was used to balance baseline characteristics between the sublobar resection and lobectomy groups. Perioperative outcomes, pulmonary function recovery, postoperative quality of life, and survival were compared between the two groups. A total of 151 patients were
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Raja Shekhar, Shano Naseem, Jogeshwar Binota et al. · 2021 · Hematology/Oncology and Stem Cell Therapy
Objective/background: B-cell neoplasms are clonal tumors of B cells at various stages of maturation, including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic lymphoma (CLL), Burkitt lymphoma (BL), lymphoplasmacytic lymphoma (LPL)/Waldenström’s macroglob- ulinemia (WM), splenic marginal zone lymphoma (SMZL), nodal marginal zone lymphoma (NMZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and hairy cell leukemia (HCL). In this study, we analyzed the frequency of MYD88 L265P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasms. Methods:
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Pedro Davila-Piñón, Pedro Davila-Piñón, Alba Nogueira-Rodríguez et al. · 2024 · Frontiers in Oncology
BackgroundPolyDeep is a computer-aided detection and classification (CADe/x) system trained to detect and classify polyps. During colonoscopy, CADe/x systems help endoscopists to predict the histology of colonic lesions.ObjectiveTo compare the diagnostic performance of PolyDeep and expert endoscopists for the optical diagnosis of colorectal polyps on still images.MethodsPolyDeep Image Classification (PIC) is an in vitro diagnostic test study. The PIC database contains NBI images of 491 colorectal polyps with histological diagnosis. We evaluated the diagnostic performance of PolyDeep and four e
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Xingwang Li, Xingwang Li, Shaoqing Guo et al. · 2025 · Frontiers in Oncology
ObjectivesThe field of view through transanal endoscopic provides new treatment approaches for solving complex clinical problems. TAMIS belongs to single-port endoscopic surgery, and the operation is complex. Analyzing the learning curve of TAMIS aims to facilitate its better clinical promotion.MethodsA retrospective cohort study analyzed the clinical data of 58 patients who underwent TAMIS by the same surgeon from January 2018 to October 2024. The learning curve of TAMIS was obtained using the cumulative sum (CUSUM) analysis, and the optimal number of surgeries was determined based on the pea
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Rathi N. Pillai, MD, Suresh S. Ramalingam, MD, Meena Thayu, MD et al. · 2021 · JTO Clinical and Research Reports
Introduction: The programmed death-ligand 1 inhibitor atezolizumab improves progression-free survival (PFS) and overall survival (OS) for patients with previously treated advanced NSCLC. Preclinical studies indicate that targeting CD38-positive cells with daratumumab may synergistically enhance atezolizumab’s antitumor activity by increasing the effector T-cell activity. Methods: This phase 1b-2 study included a safety run-in (one cycle of daratumumab plus atezolizumab) and randomized phases (daratumumab plus atezolizumab versus atezolizumab alone). The primary objective of the randomized phas
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Hironori Sadamatsu, Yuki Kurihara, Koichiro Takahashi et al. · 2019 · Case Reports in Oncology
Paraneoplastic limbic encephalitis (PLE) is a rare neurologic disorder that can complicate various malignancies, including lung cancer. PLE is most frequently found the initial presentation of lung cancer. In this study, we reported the case of a 74-year-old Japanese woman who developed PLE after partial remission of small cell lung cancer (SCLC) by first-line systemic chemotherapy. Brain magnetic resonance imaging showed no metastatic tumor or cerebrovascular disease. Anti-glutamic acid decarboxylase (GAD) and anti-amphiphysin antibodies were detected in her serum. She was diagnosed as having
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Chen F, Shen J, Wang J et al. · 2018 · Cancer Management and Research
Fawen Chen,1,2 Jing Shen,3 Jianwei Wang,1 Pengwei Cai,1 Yi Huang3 1Department of Clinical Laboratory, Fujian Provincial Hospital South Branch, 2Department of Blood Transfusion, 3Department of Clinical Laboratory, Fujian Provincial Hospital, Provincial Clinical College of Fujian Medical University, Fuzhou, People’s Republic of China Purpose: To investigate the diagnostic values of human epididymis protein 4 (HE4), carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA) for ovarian tumors. Methods: The participants were divided into three gr
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
A. DeMichele, A. C. Dueck, D. Hlauschek et al. · 2025 · Breast Cancer Research
Abstract Background The PALLAS trial investigated the addition of palbociclib to standard adjuvant endocrine therapy to reduce breast cancer recurrence. This pre-specified analysis was conducted to determine whether adjuvant palbociclib benefited patients diagnosed with lower risk stage IIA disease compared to those with higher stage disease. Methods PALLAS was an international, multicenter, randomized, open-label, phase III trial, representing a public–private partnership between Pfizer, the Austrian Breast Cancer Study Group, and the U.S. ALLIANCE Foundation. Patients diagnosed with stage II
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Jinxin Zhou, Runze Zhao, Yu Pan et al. · 2022 · Frontiers in Oncology
Accurate diagnosis and grading are critical for pancreatic neuroendocrine neoplasm (pNEN) management. This study compares the diagnostic and grading value of 68Ga-DOTATATE PET/MR and 18F-FDG PET/MR for pNENs separately as well as in combination. A total of 36 patients with histologically confirmed pNENs, who underwent both 68Ga-DOTATATE PET/MR and 18F-FDG PET/MR within 2 weeks from 2020 to 2021, were retrospectively collected and analyzed. The maximum standardized uptake values of 68Ga-DOTATATE (G-SUVmax) and 18F-FDG (F-SUVmax) on PET and the minimum values of apparent diffusion coefficient (A
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Robert G Maki, Martina Bradic, Phillip Wong et al. · 2025 · Journal for ImmunoTherapy of Cancer
Background Objective responses to immune checkpoint inhibitors (ICI) in leiomyosarcoma (LMS) are rare. Response rates may be increased by combination with other drugs known to promote immune infiltration, such as poly(ADP-ribose) polymerase (PARP) inhibitors, which have led to benefit in BRCA-altered uterine LMS. We therefore evaluated the combination of a PARP inhibitor, rucaparib, and the anti-programmed death receptor-1 monoclonal antibody, nivolumab, in patients with advanced LMS and investigated its effects on the tumor immune microenvironment.Methods This was an open-label, single-center
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Justin G. Mygatt, Jennifer Cullen, Samantha A. Streicher et al. · 2020 · Cancer Medicine
Abstract Background The relationship between race, prostate tumor location, and BCR‐free survival is inconclusive. This study examined the independent and joint roles of patient race and tumor location on biochemical recurrence‐free (BCR) survival. Methods A retrospective cohort study was conducted among men with newly diagnosed, biopsy‐confirmed, NCCN‐defined low risk CaP who underwent radical prostatectomy (RP) at the Walter Reed National Military Medical Center from 1996 to 2008. BCR‐free survival was modeled using Kaplan‐Meier estimation curves and multivariable Cox proportional hazards (P
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Sung Ui Jung, Kwang Kuk Park, Song I Yang et al. · 2014 · Korean Journal of Clinical Oncology
Purpose: Mutations in the p53 gene and accumulation of p53 protein are the most common genetic events in gastric carcinomas. This study evaluates the association of p53 gene expression with clinicopathologic findings and prognosis of gastric cancer patients who underwent curative resection. Methods: Retrospective analysis was performed on 236 consecutive patients with gastric cancer who underwent surgery at the Kosin University Gospel Hospital between December 2011 and September 2012. Nuclear p53 expression was detected by immunohistochemistry. Results: p53 expression was detected in 213 patie
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Ximena Baez-Navarro, Nadine S. van den Ende, Anh H. Nguyen et al. · 2024 · Breast Cancer Research
Abstract Most patients with triple-negative breast cancer (TNBC) are not candidates for targeted therapy, leaving chemotherapy as the primary treatment option. Recently, immunotherapy has demonstrated promising results in TNBC, due to its immunogenicity. In addition, a novel antibody–drug conjugate, namely, trastuzumab-deruxtecan, has shown effectiveness in TNBC patients with low-HER2 expression (HER2-low). These novel treatment options raise the question about the potential association between the density of stromal tumor-infiltrating lymphocytes (sTILs) and the level of HER2 expression. We a
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Yongchao Zhang, Shanshan Chen, Hualei Chen et al. · 2023 · Cancer Medicine
Abstract Background The association between Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) and clinical outcomes in patients receiving immune checkpoint inhibitors (ICIs) remains controversial. Thus, this meta‐analysis aimed to examine the prognostic performance of GPS and mGPS in patients treated with ICIs. Methods Eligible studies were retrieved from searches of EMBASE, PubMed, Web of Science, and Cochrane Library until July 2021. The hazard ratio (HR) and 95% confidence intervals (CIs) were pooled by using fixed‐effect or random‐effects model to evaluate the
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Muller Susan, Bouquot Jerry, Lou Yahuan et al. · 2007 · BMC Cancer
Abstract Background TRAIL plays an important role in host immunosurveillance against tumor progression, as it induces apoptosis of tumor cells but not normal cells, and thus has great therapeutic potential for cancer treatment. TRAIL binds to two cell-death-inducing (DR4 and DR5) and two decoy (DcR1, and DcR2) receptors. Here, we compare the expression levels of TRAIL and its receptors in normal oral mucosa (NOM), oral premalignancies (OPM), and primary and metastatic oral squamous cell carcinomas (OSCC) in order to characterize the changes in their expression patterns during OSCC initiation a
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Christian Borel, Caroline Even, Christophe Le Tourneau et al. · 2023 · BMJ Oncology
Objective Salivary gland cancers (SGC) are rare cancers with currently no standard treatment for recurrent/metastatic disease. Based on checkpoint inhibitors benefit in a broad range of tumours, NIvolumab in Salivary gland CArcinoma of the Head and Neck (NISCAHN) evaluated nivolumab efficacy in SGC.Methods and analysis In this phase II single-stage Fleming design, patients with SGC with a progressive disease progression within 6 months prior to entering the study, were divided into ACC (adenoid cytic carcinoma) and non-ACC. All received nivolumab for a maximum of 12 months. The primary endpoin
View details →Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens
Bilan Yang, Xiaoli Xi, Hongsheng Yu et al. · 2024 · Cancer Reports
Abstract Background The optimal treatment strategy for early‐stage hepatocellular carcinoma (HCC) remains controversial, specifically in regard to surgical resection (SR) and ablation. The aim of this study was to investigate the impact of SR and ablation on recurrence and prognosis in early‐stage HCC patients, to optimize treatment strategies and improve long‐term survival. Methods A retrospective analysis was conducted on 801 patients diagnosed with Barcelona Clinic Liver Cancer (BCLC) stage 0/A HCC and treated with SR or ablation between January 2015 and December 2019. The effectiveness and
View details →